Mysildecard (Sildenafil)

Sildenafil, the active ingredient in Mysildecard, is a phosphodiesterase type 5 inhibitor presented as a tablet for oral use. It treats erectile dysfunction in adult males and is also indicated for pulmonary arterial hypertension.

GNH USA supplies Mysildecard as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mysildecard (sildenafil) acts on the phosphodiesterase‑5 pathway to improve vascular smooth‑muscle relaxation in several conditions.

- Erectile dysfunction: enhances the ability to achieve and maintain an erection suitable for sexual activity. - Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity. - Male sexual dysfunction: supports satisfactory sexual performance when other therapies are insufficient.

Common side effects are generally mild and transient.

Common Side Effects: - Headache - Flushing - Dyspepsia or indigestion - Nasal congestion - Visual disturbances (e.g., blue‑tinted vision) - Back pain or muscle aches

Serious or Rare Side Effects: - Priapism (prolonged erection lasting >4 hours) - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy) - Sudden hearing loss or tinnitus - Severe hypotension, especially with nitrates - Allergic reactions such as rash or angioedema - Myocardial infarction or stroke in high‑risk patients

Before prescribing Mysildecard, clinicians should evaluate cardiovascular status and concomitant medications.

- Cardiovascular assessment: ensure patient can tolerate sexual activity. - Nitrate therapy: avoid co‑administration due to risk of severe hypotension. - Severe renal or hepatic impairment: dose adjustment may be required. - Hypotension risk: monitor patients on antihypertensives. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Sildenafil may interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): can cause profound hypotension. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure. - Alpha‑blockers (certain agents): may lead to marked blood pressure drops.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Other antihypertensives: monitor blood pressure for additive effects. - Protease inhibitors (e.g., ritonavir): may increase plasma levels. - Certain antifungals (e.g., fluconazole): may modestly raise exposure.